Florian <span>A.</span> Karreth, PhD
Researcher

Florian A. Karreth, PhD

Academic Rank: Assistant Member

View Lab Page

Overview

Discipline

    • Molecular Oncology
    • Cutaneous Oncology
    • Cancer Biology and Evolution Program

Education & Training

    • University of Vienna, MS - Genetics & Biochemistry
    • University of Vienna, PhD - Genetics
    • Beth Israel Deaconess Medical Center, Postdoc
    • Weill Cornell Medical College, Postdoc
Research

My lab is interested in the intersection of oncogenic signaling pathways and non-coding RNAs in the initiation, progression, and resistance of cancers driven by the MAPK pathway, with an emphasis on melanoma. We study how secondary genetic events enhance or cooperate with the MAPK pathway to promote the oncogenic evolution of melanoma. Such secondary events may represent targetable vulnerabilities that could be therapeutically explored in combination with current standard-of-care targeted therapy or immunotherapy.

Publications

  • Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth FA, Trevino JG, Merchant N, Magliocco A, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Sci Rep. 2017 Sep;7(1):10484. Pubmedid: 28874676. Pmcid: PMC5585319.
  • Yoon SO, Shin S, Karreth FA, Buel GR, Jedrychowski MP, Plas DR, Dedhar S, Gygi SP, Roux PP, Dephoure N, Blenis J. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Mol Cell. 2017 Aug;67(3):512-527.e4. Pubmedid: 28757207.
  • DeNicola GM, Karreth FA, Adams DJ, Wong CC. The utility of transposon mutagenesis for cancer studies in the era of genome editing. Genome Biol. 2015 Oct;16:229. Pubmedid: 26481584. Pmcid: PMC4612416.
  • Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci U S A. 2015 Feb;112(6):E536-E545. Pubmedid: 25624498. Pmcid: PMC4330752.
  • Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Wu D, Seitzer N, Velasco-Herrera Mdel C, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015 Apr;161(2):319-332. Pubmedid: 25843629.
  • Tay Y, Karreth FA, Pandolfi PP. Aberrant ceRNA activity drives lung cancer. Cell Res. 2014 Mar;24(3):259-260. Pubmedid: 24525785. Pmcid: PMC3945890.
  • Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst. 2014 Aug;106(8). Pubmedid: 25063326. Pmcid: PMC4155429.
  • Tay Y, Tan SM, Karreth FA, Lieberman J, Pandolfi PP. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep. 2014 Aug;8(3):714-722. Pubmedid: 25088422. Pmcid: PMC4128194.
  • Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013 Oct;3(10):1113-1121. Pubmedid: 24072616. Pmcid: PMC3801300.
  • Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Léopold V, Tay Y, Provero P, Zecchina R, Pandolfi PP. Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A. 2013 Apr;110(18):7154-7159. Pubmedid: 23536298. Pmcid: PMC3645534.
  • Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, Tuveson DA. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut. 2012 Jun;61(6):877-884. Pubmedid: 22157328.
  • Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011 Oct;147(2):344-357. Pubmedid: 22000013. Pmcid: PMC3235920.
  • Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011 Oct;147(2):382-395. Pubmedid: 22000016. Pmcid: PMC3236086.
  • Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 2011 Jul;1(2):128-136. Pubmedid: 22043453. Pmcid: PMC3203527.
  • DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011 Jul;475(7354):106-109. Pubmedid: 21734707. Pmcid: PMC3404470.
  • Meixner A, Karreth F, Kenner L, Penninger JM, Wagner EF. Jun and JunD-dependent functions in cell proliferation and stress response. Cell Death Differ. 2010 Sep;17(9):1409-1419. Pubmedid: 20300111.
  • Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010 Nov;18(5):499-509. Pubmedid: 21056012.
  • Karreth FA, DeNicola GM, Winter SP, Tuveson DA. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell. 2009 Nov;36(3):477-486. Pubmedid: 19917255.
  • Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev. 2009 Feb;19(1):4-11. Pubmedid: 19201597. Pmcid: PMC3389704.
  • King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006 Dec;66(23):11100-11105. Pubmedid: 17145850.
  • Karreth F, Hoebertz A, Scheuch H, Eferl R, Wagner EF. The AP1 transcription factor Fra2 is required for efficient cartilage development. Development. 2004 Nov;131(22):5717-5725. Pubmedid: 15509771.
  • Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 2004 Nov;3(11):1058-1059. Pubmedid: 15640618.
  • Meixner A, Karreth F, Kenner L, Wagner EF. JunD regulates lymphocyte proliferation and T helper cell cytokine expression. Embo J. 2004 Mar;23(6):1325-1335. Pubmedid: 15029240. Pmcid: PMC381408.
  • Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, Amling M, Wagner EF. The Fos-related antigen Fra-1 is an activator of bone matrix formation. Embo J. 2004 Jul;23(14):2789-2799. Pubmedid: 15229648. Pmcid: PMC514946.
  • Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G. Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets. 2004 Feb;15(1):29-35. Pubmedid: 14985174.
  • Kenner L, Hoebertz A, Beil FT, Beil T, Keon N, Karreth F, Eferl R, Scheuch H, Szremska A, Amling M, Schorpp-Kistner M, Angel P, Wagner EF. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol. 2004 Feb;164(4):613-623. Pubmedid: 14769860. Pmcid: PMC2171977.
  • Gruber R, Karreth F, Frommlet F, Fischer MB, Watzek G. Platelets are mitogenic for periosteum-derived cells. J Orthop Res. 2003 Sep;21(5):941-948. Pubmedid: 12919885.
  • Gruber R, Schöfnagl M, Karreth F, Fischer MB, Watzek G. The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formation. Prostag Leukotr Ess. 2003 Apr;68(4):267-272. Pubmedid: 12628222.
  • Gruber R, Karreth F, Fischer MB, Watzek G. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone. 2002 May;30(5):726-732. Pubmedid: 11996911.